The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Strategic Design of Conquering Hypoxia in Tumor for Advanced Photodynamic Therapy
Open accessAbstract
Photodynamic therapy (PDT), with its advantages of high targeting, minimally invasive, and low toxicity side effects, has been widely used in the clinical therapy of various tumors, especially superficial tumors. However, the tumor microenvironment (TME) presents hypoxia due to the low oxygen (O 2) supply caused by abnormal vascularization in neoplastic tissues and high O 2 consumption induced by the rapid proliferation of tumor cells. The efficacy of oxygen‐consumping PDT can be hampered by a hypoxic TME. To address this problem, researchers have been developing advanced nanoplatforms and strategies to enhance the therapeutic effect of PDT in tumor treatment. This review summarizes recent advanced PDT therapeutic strategies to against the hypoxic TME, thus enhancing PDT efficacy, including increasing O 2 content in TME through delivering O 2 to the tumors and in situ generations of O 2; decreasing the O 2 consumption during PDT by design of type I photosensitizers. Moreover, recent synergistically combined therapy of PDT and other therapeutic methods such as chemotherapy, photothermal therapy, immunotherapy, and gas therapy is accounted for by addressing the challenging problems of mono PDT in hypoxic environments, including tumor resistance, proliferation, and metastasis. Finally, perspectives of the opportunities and challenges of PDT in future clinical research and translations are provided.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Targeting HIF-1 for cancer therapy
Semenza, G. L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1187 · Cited by 6,717
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Wei, S. C., Duffy, C. R., & Allison, J. P. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0367 · Cited by 3,088
Juan, C. A., Pérez de la Lastra, J. M., Plou, F. J., & Pérez-Lebeña, E. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094642 · Cited by 2,810
Definition of type I and type II photosensitized oxidation
Foote, C. S. (1991) · Photochemistry and Photobiology · doi:10.1111/j.1751-1097.1991.tb02071.x · Cited by 1,248
Niu, B., Liao, K., Zhou, Y., Wen, T., Quan, G., Pan, X., & Wu, C. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.121110 · Cited by 1,168
Cheng, Y., Cheng, H., Jiang, C., Qiu, X., Wang, K., Huan, W., Yuan, A., Wu, J., & Hu, Y. (2015) · Nature Communications · doi:10.1038/ncomms9785 · Cited by 941
Emami Nejad, A., Najafgholian, S., Rostami, A., Sistani, A., Shojaeifar, S., Esparvarinha, M., Nedaeinia, R., Haghjooy Javanmard, S., Taherian, M., Ahmadlou, M., et al. (2021) · Cancer Cell International · doi:10.1186/s12935-020-01719-5 · Cited by 693
Catalase-Integrated Hyaluronic Acid as Nanocarriers for Enhanced Photodynamic Therapy in Solid Tumor
Phua, S. Z. F., Yang, G., Lim, W. Q., Verma, A., Chen, H., Thanabalu, T., & Zhao, Y. (2019) · ACS Nano · doi:10.1021/acsnano.9b01087 · Cited by 375
Sun, Y., Zhao, D., Wang, G., Wang, Y., Cao, L., Sun, J., Jiang, Q., & He, Z. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.01.004 · Cited by 250
Singlet Oxygen “Afterglow” Therapy with NIR‐II Fluorescent Molecules
Zou, J., Li, L., Zhu, J., Li, X., Yang, Z., Huang, W., & Chen, X. (2021) · Advanced Materials · doi:10.1002/adma.202103627 · Cited by 155
Self-citation
Cited by
Alvarez, N., & Sevilla, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25021023 · Cited by 254
Guo, X., Han, L., Chen, W., He, H., Zhang, W., Huang, C., & Wang, X. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s432407 · Cited by 14
Metadata
- Authors
- Zhang, C., Hu, X., Jin, L., Lin, L., Lin, H., Yang, Z., & Huang, W.
- Venue
- Advanced Healthcare Materials
- Publisher
- Wiley
- Published
- 2023-05-10
- Volume
- 12
- Issue
- 24
- Pages
- e2300530-e2300530
- ISSN
- 2192-2640 (ISSN-L)
- 2192-2659
- OpenAlex
- W4367052473
- Cited by
- 158
- References
- 11
- FWCI
- 25.10
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.